# Dermatology Times

> Dermatology Times - Healthcare Publication

- Base URL: https://www.dermatologytimes.com
- Generated: 2026-10-19T00:58:56.976Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.dermatologytimes.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.dermatologytimes.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.dermatologytimes.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.dermatologytimes.com/robots.txt](https://www.dermatologytimes.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Aclinical Dermatitis](https://www.dermatologytimes.com/aclinical dermatitis)
- [Around the Practice](https://www.dermatologytimes.com/around-the-practice)
- [Between The Lines](https://www.dermatologytimes.com/between-the-lines)
- [Case-Based Peer Perspective](https://www.dermatologytimes.com/case-based-peer-perspective)
- [Clinical](https://www.dermatologytimes.com/clinical)
- [Clinical Case Collective](https://www.dermatologytimes.com/clinical-case-collective)
- [Clinical Role](https://www.dermatologytimes.com/clinical-role)
- [Conferences](https://www.dermatologytimes.com/conferences)
- [Conferences (Dont Use)](https://www.dermatologytimes.com/conference)
- [DermView](https://www.dermatologytimes.com/dermview)
- [Inside the Clinic](https://www.dermatologytimes.com/inside-the-clinic)
- [NO ADS](https://www.dermatologytimes.com/no-ads)
- [News](https://www.dermatologytimes.com/news)
- [Patient Perspectives](https://www.dermatologytimes.com/patient-perspectives)
- [Podcasts](https://www.dermatologytimes.com/podcasts)
- [Recognize and Refer](https://www.dermatologytimes.com/recognize-and-refer)
- [Resources](https://www.dermatologytimes.com/resources)
- [Role](https://www.dermatologytimes.com/role)
- [Video Series](https://www.dermatologytimes.com/video-series)
- [Viewpoints](https://www.dermatologytimes.com/viewpoints)

## Featured Content

- [Social Media Mythbusters: Can Castor Oil Really Grow Hair?](https://www.dermatologytimes.com/view/social-media-mythbusters-can-castor-oil-really-grow-hair-): Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains lim...
- [GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease](https://www.dermatologytimes.com/view/glp-1-agonists-address-metabolic-risk-in-psoriatic-disease): Joel Gelfand, MD, MSCE, discussed the role of GLP-1 agonists in addressing the metabolic comorbidities of psoriatic disease at Fall Clinical 2026.
- [EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance](https://www.dermatologytimes.com/view/eb06-phase-2-vitiligo-study-receives-fda-ind-clearance): The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in th...
- [PA Burnout Persists as Workload, Pay, and Administrative Burdens Take a Toll](https://www.dermatologytimes.com/view/pa-burnout-persists-as-workload-pay-and-administrative-burdens-take-a-toll): A 2026 Medscape survey found that burnout remains a significant concern among PAs, with bureaucratic demands, inadequate compensation, and long workin...
- [CIndU Treatment Algorithm: Antihistamine Up-Titration and Unmet Needs](https://www.dermatologytimes.com/view/cindu-treatment-algorithm-antihistamine-up-titration-and-unmet-needs): A methodical up-titration schedule and clear expectations help patients reach the point where advanced therapy is appropriate. With no approved CIndU...
- [CIndU Antihistamines: Why Second-Generation H1 Therapy Falls Short for Many](https://www.dermatologytimes.com/view/cindu-antihistamines-why-second-generation-h1-therapy-falls-short-for-many): Second-generation H1 antihistamines remain first-line therapy, yet most patients do not reach control even at higher doses. The panel outlines where a...
- [Don't Be Rash: Balancing Topical Steroids in the Era of Nonsteroidals](https://www.dermatologytimes.com/view/don-t-be-rash-balancing-topical-steroids-in-the-era-of-nonsteroidals): On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes  Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical cortic...
- [FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults](https://www.dermatologytimes.com/view/fda-approves-pritelivir-for-refractory-mucocutaneous-hsv-in-immunocompromised-adults): The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treat...
- [EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data](https://www.dermatologytimes.com/view/eadv-2026-atopic-dermatitis-highlights-tilrekimig-rac2-inhibition-and-level-up-data): Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib.
- [Exosome Progress and Remibrutinib Label Expansion](https://www.dermatologytimes.com/view/exosome-progress-and-remibrutinib-label-expansion): At Fall Clinical 2026, Todd Schlesinger, MD, explained recent exosome regulatory progress, the remibrutinib label update for symptomatic dermographism...

## Feeds and Indexes

- [RSS Feed](https://www.dermatologytimes.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.dermatologytimes.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.dermatologytimes.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.dermatologytimes.com/authors): Browse all contributors and their published work